Gastroenterology

The prevalence of CDI in southern China was 11.0% and 13.6% in northern China.

The results show concomitant recurrent CDI was associated with an IBD flare in 54% of participants. Of this group, 63% received IBD remission-induction therapy before FMT.

Recent data during ECCO 23 show ustekinumab results in higher rates of clinical remission and clinical response in patients with inflammatory bowel disease.

Neutropenia, male gender, high serum creatinine, and albumin were all associated with fatal outcomes.

There was a 0.9% increase in the first dispensation of infliximab, either the biosimilar or originator during the first year of follow-up, as well as a 16.2% increase in infliximab dose escalation, a 2.4% decrease in the dispensation of antibiotics, and a 2.6% decrease in the new use of prednisone.

The results show 58% of patients treated with ustekinumab were in clinical remission, while 80% were in clinical response.

The gene expression analysis of the liver showed mRNA levels of BCAT1, BCAT2, and BCKDA were upregulated in patients with NAFLD.

The mortality rate ranged from 13.2 deaths per 100,000 live births in 2005 to 8.3 deaths per 100,000 live births in 2020.

Much of the recent focus on drug development in IBD has centered on the IL-23 pathway.

Data from AAAAI 2023 suggests that gut microbial composition, function, and metabolic activity are implicated in the efficacy of peanut oral immunotherapy in children with peanut allergy.

The patients that did not undergo colectomy in the infliximab group were more often re-hospitalized because to the need for intravenous corticosteroids at the two-year follow-up compared to the cyclosporine group.

Individuals that did not respond had a lower percentage of naïve T cells compared to responders, while responders had a lower percentage of Th2 and CD4 central memory subsets before vaccination.

There was also an inverse correlation between FGF21 levels and nutritional status indicators, including body mass index, albumin level, and cholesterol in patients with inflammatory bowel disease.

The results suggest CRP and fCal could be useful markers of histology and endoscopy outcomes for biologic-naïve patients with inflammatory bowel disease.

This group also had a longer time to event of first IBD-related hospitalization and primary and secondary IBD-related surgery in patients without a history of IBD-related surgery at baseline.

There were no differences found in the total thickness of other esophageal regions, dysphagia score, endoscopic appearance, and eosinophil count over time.

Individuals with comorbid asthma, allergic rhinitis, and oral allergy syndrome had higher rates of eosinophilic esophagitis.

The results show methotrexate exposure time and cumulative doses were not predictors for fibrosis, but alcohol was a predictor.

The most common invasive fungal infection was histoplasmosis and the risk of invasive fungal infections was more than double in patients treated with corticosteroids than it was for patients treated with anti-TNFs.

The results show a placebo-controlled trial is warranted in the future.

Patients who were PCR positive or likely colonized in the two-step era were 20 times less likely to be associated with treatment for CDI, without adversely impacting patient outcomes.

FMT was cost-effective compared to vancomycin in both the general CDI population, as well as the subset of patients with IBD. However, it was less cost-effective in compared to fidaxomicin.

There was a 2.35-fold risk increase in PCCRC in the lowest ADR group compared to the highest.

There were no serious adverse events in the group of patients treated with colesevelam.

From new ACG GERD guidelines to the efficacy of colonoscopies, our latest issue addresses topics changing practice and stirring conversation.